Wolters Kluwer N.V. (WOLTF)
| Previous close | 161.33 |
| Open | 161.33 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 161.33 - 161.33 |
| 52-week range | 111.91 - 161.33 |
| Volume | |
| Avg. volume | 25 |
| Market cap | 38.461B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 37.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.24 (1.39%) |
| Ex-dividend date | 10 May 2024 |
| 1y target est | N/A |
- Business Wire
Wolters Kluwer introduces Regulatory Audit Module to improve risk adjustment audit validation rates using AI
WALTHAM, Mass., April 17, 2024--The Wolters Kluwer Health Regulatory Audit Module helps mitigate Risk Adjustment Data Validation (RADV) audits and extrapolation.
- Business Wire
Wolters Kluwer announces two senior executive appointments
NEW YORK, April 17, 2024--Wolters Kluwer, a global leader in information, software, and services for professionals, today announced Atul Dubey as General Manager of its Finance, Risk and Regulatory Reporting (FRR) business, part of its Corporate Performance & ESG (CP & ESG) division. Suzanne Konstance will succeed Dubey as General Manager of Wolters Kluwer Legal & Regulatory U.S, part of the company’s Legal & Regulatory division, effective May 1.
- Business Wire
Wolters Kluwer Survey: Over Two-Thirds of U.S. Physicians Have Changed Their Mind, Now Viewing GenAI as Beneficial in Healthcare
WALTHAM, Mass., April 16, 2024--A Wolters Kluwer Health survey finds 68% of U.S. physicians changed views in the last year, now more likely view GenAI as beneficial to healthcare.
